Sriram Sathy, Ph.D.

Vice President, Biology and Translational Science

Sriram Sathy joined Codiak from Jounce Therapeutics, where is was Senior Director of Clinical development and was responsible for building their translational science platform.

There he developed and implemented an integrated translational discovery strategy that develop patient enrichment biomarkers and indication selection and new target identification which helped transform Jounce to a publicly-traded research and development organization. Before joining Jounce, Dr. Sathy spent 6 years at Merck & Co, leading the translational oncology strategy for their multi-oncology programs that established clinical Proof of Concept (POC) for a novel combination therapy.

Earlier in his career, Dr. Sathy was working in the field of Circadian Rhythms as a Post-Doctoral Fellow at the University of Pennsylvania School of Medicine & Howard Hughes Medical Institute in Philadelphia and Massachusetts General Hospital and Harvard Medical School.

He has his PhD from the Indian Institute of Science, Bangalore, India in Microbiology and Cell Biology and holds his BS and MS from PSG Collage of Arts & Science, Coimbatore, India in Biochemistry. In addition to his strong academic accomplishments, he has published extensively in immune-oncology translational and clinical research.